Conception and reality: Outcome of SARS-CoV-2 infection and vaccination among Hungarian IBD patients on biologic treatments.

Biologic treatment Inflammatory bowel disease Pandemic SARS-CoV-2

Journal

Vaccine: X
ISSN: 2590-1362
Titre abrégé: Vaccine X
Pays: England
ID NLM: 101748769

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 04 04 2022
revised: 03 11 2022
accepted: 21 12 2022
pubmed: 28 12 2022
medline: 28 12 2022
entrez: 27 12 2022
Statut: ppublish

Résumé

Inflammatory bowel disease potentially elevates the risk of infections, independently from age, while the disease activity and medical treatment(s) can also increase the risks. Nevertheless, it is necessary to clarify these preconceptions as well during the COVID-19 pandemic. An observational, questionnaire based study was conducted in Hungary between February and August 2021. 2 questionnaires were completed. The first questionnaire surveyed the impact of the pandemic on patients with biologic treatments and assessed the severity and outcome of the infection, whereas the second one assessed vaccination rate and adverse events. 472 patients participated in the study. 16.9 % of them acquired the infection and 6.3 % needed hospitalization. None of them required ICU care. Male sex elevated the risk of infection (p = 0.008), while glove (p = 0.02) and mask wearing (p = 0.005) was the most effective prevention strategy. Nevertheless, abstaining from community visits or workplace did not have an impact on the infection rate. Smoking, age, and disease type did not elevate the risk. UC patients had poorer condition during the infection (p = 0.003); furthermore, the disease activity could potentially worsen the course of infection (p = 0.072). The different biological treatments were equally safe; no difference was observed in the infection rate, course of COVID-19. Azathioprine and corticosteroids did not elevate the infection rate. 28 patients (35.0 %) suspended the ongoing biologic treatment, but it had no impact on the disease course. However, it resulted in changing the current treatment (p = 0.004). 9.8 % of the respondents were sceptic about being vaccinated, and 90 % got vaccinated. In one case, a serious flare-up occurred. Most patients acquired the infection at workplace. Biologic therapies had no effect on the COVID-19 infection, whereas male sex, an active disease, and UC could be larger threat than treatments. Vaccination was proved to be safe, and patient education is important to achieve mass vaccination of the population.

Identifiants

pubmed: 36573242
doi: 10.1016/j.jvacx.2022.100253
pii: S2590-1362(22)00113-9
pmc: PMC9773695
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100253

Informations de copyright

© 2022 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

United European Gastroenterol J. 2019 Nov 14;8(3):303-313
pubmed: 32529821
Am J Gastroenterol. 2011 Apr;106(4):741-7
pubmed: 21386828
Inflamm Bowel Dis. 2019 Jan 10;25(2):369-376
pubmed: 30020478
J Crohns Colitis. 2021 Apr 6;15(4):529-539
pubmed: 33079178
Dig Liver Dis. 2021 Mar;53(3):271-276
pubmed: 33451910
Gastroenterology. 2018 Aug;155(2):337-346.e10
pubmed: 29655835
Gastroenterology. 2020 Aug;159(2):481-491.e3
pubmed: 32425234
Gut. 2020 Jul;69(7):1213-1217
pubmed: 32354990
Thorax. 2022 Jan;77(1):65-73
pubmed: 34580193
J Gen Intern Med. 2020 May;35(5):1545-1549
pubmed: 32133578
Br J Clin Pharmacol. 1999 Oct;48(4):481-4
pubmed: 10583016
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Aliment Pharmacol Ther. 2020 Jun;51(12):1434-1437
pubmed: 32311755
Adv Virus Res. 2011;81:85-164
pubmed: 22094080
J Crohns Colitis. 2014 Jun;8(6):443-68
pubmed: 24613021
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):561-565
pubmed: 32413819
Sci Rep. 2021 Sep 27;11(1):19143
pubmed: 34580322
Expert Rev Gastroenterol Hepatol. 2021 Apr;15(4):465-466
pubmed: 33576700
United European Gastroenterol J. 2021 Mar;9(2):159-176
pubmed: 33210980
Gut. 2020 Jul;69(7):1335-1342
pubmed: 32303609
Am J Gastroenterol. 2013 Feb;108(2):240-8
pubmed: 23295276
Aging Clin Exp Res. 2020 Jul;32(7):1195-1198
pubmed: 32377965

Auteurs

Tamás Resál (T)

Gastroenterology Unit, Department of Medicine, University of Szeged, Szeged, Hungary.

Mária Matuz (M)

Department of Clinical Pharmacy, University of Szeged, Szeged, Hungary.

Csilla Keresztes (C)

Department for Medical Communication and Translation Studies, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.

Péter Bacsur (P)

Gastroenterology Unit, Department of Medicine, University of Szeged, Szeged, Hungary.

Kata Szántó (K)

Gastroenterology Unit, Department of Medicine, University of Szeged, Szeged, Hungary.

Anett Sánta (A)

Gastroenterology Unit, Department of Medicine, University of Szeged, Szeged, Hungary.

Mariann Rutka (M)

Gastroenterology Unit, Department of Medicine, University of Szeged, Szeged, Hungary.

Diána Kolarovszki-Erdei (D)

Gastroenterology Unit, Department of Medicine, University of Szeged, Szeged, Hungary.

Renata Bor (R)

Gastroenterology Unit, Department of Medicine, University of Szeged, Szeged, Hungary.

Anna Fábián (A)

Gastroenterology Unit, Department of Medicine, University of Szeged, Szeged, Hungary.

Zoltán Szepes (Z)

Gastroenterology Unit, Department of Medicine, University of Szeged, Szeged, Hungary.

Pál Miheller (P)

Department of Surgery and Interventional Gastroenterology, Semmelweis University, Budapest, Hungary.

Patrícia Sarlós (P)

Gastroenterology Unit, 1st Department of Medicine, University of Pécs, Pécs, Hungary.

Anita Zacháry (A)

Hungarian Crohn's and Colitis Association, Budapest, Hungary.

Klaudia Farkas (K)

Gastroenterology Unit, Department of Medicine, University of Szeged, Szeged, Hungary.

Tamás Molnár (T)

Gastroenterology Unit, Department of Medicine, University of Szeged, Szeged, Hungary.

Classifications MeSH